Members called Verve-102, a one-time PCSK9 gene edit, remarkable science that is not ready for patients.
The concerns: no long-term safety data, the edit is irreversible, off-target editing has been seen in the adrenals and spleen, and there are no outcomes data. The group is watching.
Key takeaways
- Do not position one-shot gene editing as an option for patients yet.
- Watch for long-term safety and outcomes data.
From Buzz in the chat, the longevitydocs™ Sunday newsletter, May 31, 2026. Member discussion, not clinical guidance.
Originally published in The Longevity Medicine Intelligence newsletter.
WRITTEN BYlongevitydocs™ editorsCurated by the longevitydocs™ editorial team from the weekly newsletter
